NEUROIMMUNOLOGY PATIENT RESPONSE TO COVID-19 OUTBREAK
Enrolling By Invitation
18-99 years
All
Phase
N/A
500 participants needed
1 Location
Brief description of study
The purpose of this research study is to understand how our patients with Multiple Sclerosis (MS) and other neuroimmune disorders are being affected by the COVID-19 outbreak. We want to understand how susceptible our patients are to COVID-19. We also want to evaluate the longer-term social and psychological consequences of the pandemic for individuals who have chronic neuroimmune diseases. We are also inviting healthy individuals to participate in this study as controls.
Detailed description of study
This
study will employ prospective data collection and review of medical records. It
is an observational, non-interventional study. Participants will be provided
with a longitudinal set of online questionnaires to assess response to the
COVID-19 outbreak. Information surrounding their neurologic diagnosis will be
verified from their medical records. A set of surveys will be sent out every
2-4 weeks, and each set of surveys will require approximately 10-30 minutes to
complete. There will be 16 total sets of surveys over 52 weeks. No in-person
visits or testing are required. Your
participation will last for approximately 2 years.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Both multiple sclerosis patients & healthy participants
-
Age: Between 18 Years - 99 Years
-
Gender: All
Diagnosis of MS, neuromyelitis optica, anti-MOG
disease, autoimmune encephalitis, neurosarcoidosis OR lack of neurologic
diagnosis (as above) and is a healthy household member of an individual with a
qualifying diagnosis.
Updated on
01 Aug 2024.
Study ID: 843454
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
